Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 463.56% and ...

A GP has explained, week by week, what changes you will see - including how much weight you will lose in the first month ...

Drugs like Ozempic, Wegovy and Mounjaro are changing the game for weight loss. GLP-1 medications were originally intended to ...

A dietetics professor explains who should and should not embrace the latest weight-loss drugs. Holiday weight gain hits home ...

Eli Lilly's stock dipped due to cutting Q4 sales targets, despite a strong 2024 performance from Mounjaro and Zepbound. Click ...

Pharmacy professor Nicole Albanese discusses the science behind drugs like Ozempic and Wegovy, their potential to treat other ...

Next to artificial intelligence, weight-loss drugs have been one of the biggest themes investors latched onto in 2024. Eli ...

Eli Lilly (NYSE: LLY) saw its stock decline sharply by 6.5% on January 14, following the release of its fourth-quarter 2024 ...

A survey of 1,000 women, aged 30 to 75, found most were considering taking the likes of Wegovy and Mounjaro to help them lose ...

Unfortunately for the company, however, the early glimpse at its fourth-quarter performance doesn’t seem to be going over ...

Heading into fiscal 2025, CEO David Ricks said the company expects sales of weight-loss drugs will continue growing, and noted that it expects "to produce at least 60% more salable doses" of the drugs ...

For the first time in over a decade, obesity rates have dropped in the United States. A recent study by the CDC showed that from 2021 to 2023, those rates dropped from 41.9% to 40.3%.